Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement - PR Newswire (press release)

Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement PR Newswire (press release) The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation ...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iKO3z1
via IFTTT